Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00083135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Children's Hospital Los Angeles to New Approaches to Neuroblastoma Therapy Consortiumv24
  2. Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium to Children's Hospital Los Angeles Study title shortened, about 5 wordsv23 Show 1 more changeShow less
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Publications: 1 to 2v22 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Active, Not Recruiting to Completed Primary completion date: Feb 2006v21 Show 1 more changeShow less
    • Primary completion date: Feb 2006
  5. Interventions: autologous bone marrow transplantation (Procedure), filgrastim (Biological), iodine I 131 metaiodobenzylguanidine (Radiation), peripheral… to autologous bone marrow transplantation (Procedure), filgrastim (Biological), iobenguane I 131 (Radiation), peripheral blood stem cell…v20
Show 18 earlier versionsHide 18 earlier versions
  1. Study Status, Referencesv19
  2. Interventions: autologous bone marrow transplantation (Procedure), filgrastim (Drug), iodine I 131 metaiodobenzylguanidine (Drug), peripheral blood stem… to autologous bone marrow transplantation (Procedure), filgrastim (Biological), iodine I 131 metaiodobenzylguanidine (Radiation), peripheral…v18
  3. Re-verified, no change to tracked fieldsv17
  4. Interventions: autologous bone marrow transplantation (Procedure), colony-stimulating factor therapy (Procedure), filgrastim (Drug), iodine I 131… to autologous bone marrow transplantation (Procedure), filgrastim (Drug), iodine I 131 metaiodobenzylguanidine (Drug), peripheral blood stem…v16
  5. 2 versions Re-verified since Dec 1, 2007, no change to tracked fieldsv14-v15
  6. Interventions: autologous bone marrow transplantation (Procedure), biological therapy (Procedure), bone marrow ablation with stem cell support… to autologous bone marrow transplantation (Procedure), colony-stimulating factor therapy (Procedure), filgrastim (Drug), iodine I 131…v13
  7. Lead sponsor: National Cancer Institute (NCI) to New Approaches to Neuroblastoma Therapy Consortium Enrollment target: 18 · Start date: Mar 2004 · Study description expanded, about 5 words · 1 morev12 Show 4 more changesShow less
    • Enrollment target: 18
    • Start date: Mar 2004
    • Study description expanded, about 5 words
    • Collaborators expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  8. Trial status: Recruiting to Active, Not Recruiting Site details revised at 7 of 7 sitesv11 Show 1 more changeShow less
    • Site details revised at 7 of 7 sites
  9. Re-verified, no change to tracked fieldsv10
  10. Interventions: autologous bone marrow transplantation (Procedure), biological response modifier therapy (Procedure), bone marrow ablation with stem cell… to autologous bone marrow transplantation (Procedure), biological therapy (Procedure), bone marrow ablation with stem cell support…v9
  11. Study sites revised (7)v8 See this version in full on ClinicalTrials.gov ↗
  12. Site contacts updated at 1 of 7 sitesv7
  13. Site contacts updated at 4 of 7 sitesv6
  14. Study sites: 9 to 7v5
  15. Site contacts updated at 1 of 9 sitesv4
  16. Study sites: 8 to 9v3
  17. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Giving iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) may kill neuroblastoma cells by delivering radiation directly to the tumor. A stem cell transplant using the patient's stem cells may be able to replace blood-forming cells destroyed by radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of a double infusion of \^131I-MIBG followed by autologous stem cell transplantation in treating patients with refractory neuroblastoma.
Trial Details
NCT Number NCT00083135
Lead Sponsor New Approaches to Neuroblastoma Therapy Consortium
Collaborators: National Cancer Institute (NCI)
Conditions Neuroblastoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Updated on ClinicalTrials.gov